Spinal muscular atrophy is a type of hereditary disease that affects the central & peripheral nervous system and voluntary muscle movement. It is linked to chromosome 5q (SMA) and caused by bi-allelic mutations in the SMN1 gene. It can lead to weakness and may cause death. Spinal muscular atrophy can be divided into type I, type II, type III, and type IV, depending upon variation in cause and symptoms observed. The treatment of SMA includes gene replacement therapy and drugs that may be administered to increase survival motor neuron protein levels.
MARKET SCOPE
The "Global Spinal Muscular Atrophy Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the spinal muscular atrophy treatment market with detailed market segmentation by disease type, treatment, route of administration, and geography. The report provides key statistics on the market status of the leading spinal muscular atrophy treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on disease type, the global spinal muscular atrophy treatment market is segmented into type 1, type 2, type 3 and type 4.
- Based on treatment, the market is segmented into gene therapy, drug therapy and others.
- On the basis of route of administration, the market is bifurcated into oral and intrathecal.
MARKET DYNAMICS
Drivers:
- Growing awareness for spinal muscular atrophy (SMA), its diagnostics & treatment.
- Increase in the R & D activities to develop novel treatment regimens for rare diseases.
- Rapid technological advancements.
- Increase in the government initiatives to improve healthcare infrastructure.
Restraints:
- High cost of SMA treatment.
- Lack of skilled professionals for physiotherapy regimens & surgical procedures.
- Limited access to treatment of SMA.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The spinal muscular atrophy treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the spinal muscular atrophy treatment market in these regions.
IMPACT OF COVID-19ON SPINAL MUSCULAR ATROPHY TREATMENT MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The ongoing pandemic has resulted in a worldwide healthcare crisis. Physicians and patients that visited hospitals for various treatments were at increased risk of contracting COVID-19; therefore, the government of various countries imposed lockdown and restrictive measures to prevent the transmission of infection, and despite the urgency to treat SMA patients, the delivery of treatment to individuals affected by SMA was impacted. The non-essential procedures were canceled or postponed, and only emergency procedures were allowed to be performed, impacting the SMA treatment market growth. However, the market may experience growth after the removal of restrictive measures in the forecast period.
MARKET PLAYERS
The report covers key developments in the spinal muscular atrophy treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from spinal muscular atrophy treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for spinal muscular atrophy treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the spinal muscular atrophy treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Novartis International AG
- Pfizer Inc.
- Biogen Inc.
- F. Hoffmann - La Roche Ltd
- Cytokinetics, Inc.
- Ionis Pharmaceuticals Inc.
- Natera, Inc
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- PerkinElmer, Inc.